Galena Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 95   

Articles published

GALE 1.68 -0.05 (-2.89%)
price chart
Analyst Price Target Update on Galena Biopharma, Inc.
Galena Biopharma, Inc. (NASDAQ:GALE): According to 5 Analysts, The short term target price has been estimated at $ 4.9.
Galena Biopharma (GALE) Is Today's Dead Cat Bounce Stock
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care.
Galena Biopharma, Inc. (NASDAQ:GALE) Stock Rating Update  Investor Newswire
Galena Biopharma, Inc. Analyst Rating Update  News Watch International
Active Stocks: Galena Biopharma Inc (NASDAQ:GALE), Navios Maritime ...
Galena Biopharma Inc (NASDAQ:GALE) belongs to Healthcare sector. Its weekly performance is -8.20%. On last trading day company shares ended up $1.68.
Stock Activity: Pacific Ethanol (NASDAQ:PEIX), Penn Virginia Corporation ...  Property Mentor
Catch These 3 Fast-Moving Stocks: Galena Biopharma Inc (NASDAQ:GALE ...
Galena Biopharma Inc (NASDAQ:GALE) grew 13% on Friday, keeping up its gaining momentum after the cancer drug developer reported in late May promising data from a clinical study of a second potential cancer vaccine.
Galena Biopharma, Inc. (NASDAQ:GALE) Analyst Rating Update
As many as 6 brokerage firms have rated Galena Biopharma (NASDAQ:GALE) at 2.17. Research Analysts at Zacks have ranked the company at 2, suggesting the traders with a rating of buy for the short term.
Hot Action in 4 Biotech Stocks - Galena Biopharma Inc (NASDAQ:GALE), Dyax ...  Wall Street Observer
Galena Biopharma Sees Significant Growth in Short Interest (GALE)  Dakota Financial News
Roth Capital Offers Commentary on Galena Biopharma Inc Following ...
Roth Capital analyst Joseph Pantginis offered commentary on Galena Biopharma Inc (NASDAQ:GALE) following the presentation of the Phase 2 clinical trial of GALE-401 at the European Hematology Association 20th Congress in Vienna, Austria.
Company Shares of Galena Biopharma, Inc. Drops by -15.25%  News Watch International
Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase ...  MarketWatch
Ratings Watch - Galena Biopharma, Inc. (NASDAQ:GALE)
Shares of Galena Biopharma, Inc. (NASDAQ:GALE) have been given a consensus rating of 2.17 by brokerage analysts covering the stock.
Company Shares of Galena Biopharma, Inc. Drops by -0.57%
Galena Biopharma, Inc. (NASDAQ:GALE) has dropped 0.57% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 12.1% in the last 4 weeks.
Zacks Short Term Rating on Galena Biopharma, Inc. (NASDAQ:GALE)
As much as 6 analysts have advised buy on Galena Biopharma, Inc. (NASDAQ:GALE) with an average broker rating of 2.17.
Biotech Stocks leaving investors heartbroken – Galena Biopharma Inc (NASDAQ ...  Wall Street Observer
Galena Biopharma Receives Average Rating of "Buy" from Analysts ...  Dakota Financial News
Galena Biopharma (GALE) Highlighted As Weak On High Volume
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care.